{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:01:13Z","timestamp":1791414073876,"version":"4.3.3"},"reference-count":50,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.jdiacomp.2019.06.007","type":"journal-article","created":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T14:43:47Z","timestamp":1562078627000},"page":"107402","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes: A post hoc analysis of 10 randomized, placebo-controlled trials"],"prefix":"10.1016","volume":"33","author":[{"given":"Robert D.","family":"Toto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Goldenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn M.","family":"Chertow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Cain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bergur V.","family":"Stef\u00e1nsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. David","family":"Sj\u00f6str\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Sartipy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0005","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s40620-014-0140-6","article-title":"Magnesium in CKD: more than a calcification inhibitor?","volume":"28","author":"Floege","year":"2015","journal-title":"J Nephrol"},{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0010","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2018-000775","article-title":"Magnesium for the prevention and treatment of cardiovascular disease","volume":"5","author":"DiNicolantonio","year":"2018","journal-title":"Open Heart"},{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2337\/db15-1028","article-title":"Hypomagnesemia in type 2 diabetes: a vicious circle?","volume":"65","author":"Gommers","year":"2016","journal-title":"Diabetes."},{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0020","doi-asserted-by":"crossref","first-page":"366","DOI":"10.2215\/CJN.02960906","article-title":"Hypomagnesemia in patients with type 2 diabetes","volume":"2","author":"Pham","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0025","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/07315724.2018.1476194","article-title":"Association between magnesium status, dietary magnesium intake, and metabolic control in patients with type 2 diabetes mellitus","volume":"38","author":"Ozcaliskan Ilkay","year":"2019","journal-title":"J Am Coll Nutr"},{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0030","doi-asserted-by":"crossref","first-page":"429","DOI":"10.5414\/CNP63429","article-title":"Lower serum magnesium levels are associated with more rapid decline of renal function in patients with diabetes mellitus type 2","volume":"63","author":"Pham","year":"2005","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074355","article-title":"The relationship between hypomagnesemia, metformin therapy and cardiovascular disease complicating type 2 diabetes: the Fremantle Diabetes Study","volume":"8","author":"Peters","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0040","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3945\/ajcn.112.053132","article-title":"Circulating and dietary magnesium and risk of cardiovascular disease: a systematic review and meta-analysis of prospective studies","volume":"98","author":"Del Gobbo","year":"2013","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0045","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.2337\/dc12-0226","article-title":"Hypomagnesemia in type 2 diabetic nephropathy: a novel predictor of end-stage renal disease","volume":"35","author":"Sakaguchi","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0050","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.4103\/2230-8210.103020","article-title":"Hypomagnesemia in type 2 diabetes mellitus","volume":"16","author":"Dasgupta","year":"2012","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0055","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1475-2840-11-23","article-title":"Low serum magnesium concentrations are associated with a high prevalence of premature ventricular complexes in obese adults with type 2 diabetes","volume":"11","author":"Del Gobbo","year":"2012","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0060","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/0735-1097(96)00089-7","article-title":"Hypomagnesemia: characterization of a model of sudden cardiac death","volume":"27","author":"Fiset","year":"1996","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0065","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s13300-014-0089-4","article-title":"Sodium glucose co-transporter-2 (SGLT2) inhibitors: a review of their basic and clinical pharmacology","volume":"5","author":"Kalra","year":"2014","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0070","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet."},{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0075","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"EMPA-REG OUTCOME investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0080","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0085","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"DECLARE\u2013TIMI 58 investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0090","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. Standards of medical care in diabetes\u20142019. Diabetes Care. 2019;42(Suppl 1).","DOI":"10.2337\/dc19-Sdis01"},{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0095","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1007\/s00125-016-4101-6","article-title":"Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials","volume":"59","author":"Tang","year":"2016","journal-title":"Diabetologia."},{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0100","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s13300-017-0232-0","article-title":"Effects of canagliflozin on serum magnesium in patients with type 2 diabetes mellitus: a post hoc analysis of randomized controlled trials","volume":"8","author":"Gilbert","year":"2017","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0105","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.356","article-title":"Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control","volume":"85","author":"Kohan","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0110","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.dsx.2017.08.003","article-title":"SGLT2 inhibitors-induced electrolyte abnormalities: an analysis of the associated mechanisms","volume":"12","author":"Filippatos","year":"2018","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0115","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2337\/dc10-0612","article-title":"Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"33","author":"Ferrannini","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0120","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/dme.12624","article-title":"Efficacy and safety of dapagliflozin monotherapy in people with type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial","volume":"32","author":"Bailey","year":"2015","journal-title":"Diabetes Med"},{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0125","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1742-1241.2012.02911.x","article-title":"Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial","volume":"66","author":"Henry","year":"2012","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0130","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Bailey","year":"2010","journal-title":"Lancet."},{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0135","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1741-7015-11-43","article-title":"Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial","volume":"11","author":"Bailey","year":"2013","journal-title":"BMC Med"},{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0140","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/dom.12189","article-title":"Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin","volume":"16","author":"Bolinder","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0145","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/j.1463-1326.2011.01434.x","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial","volume":"13","author":"Strojek","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0150","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2337\/dc11-1693","article-title":"Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy","volume":"35","author":"Rosenstock","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0155","doi-asserted-by":"crossref","first-page":"740","DOI":"10.2337\/dc13-0467","article-title":"Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study","volume":"37","author":"Jabbour","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0160","doi-asserted-by":"crossref","first-page":"405","DOI":"10.7326\/0003-4819-156-6-201203200-00003","article-title":"Dapagliflozin 006 study group. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial","volume":"156","author":"Wilding","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0165","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/dom.12187","article-title":"Dapagliflozin 006 Study Group. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years","volume":"16","author":"Wilding","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0170","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.2337\/dc14-0315","article-title":"Dapagliflozin's effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension","volume":"38","author":"Cefalu","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0175","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/jgs.12881","article-title":"Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension","volume":"62","author":"Leiter","year":"2014","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0180","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1046\/j.1365-2796.2000.00585.x","article-title":"Hypomagnesemia in heart failure with ventricular arrhythmias. Beneficial effects of magnesium supplementation","volume":"247","author":"Ceremuzy\u0144ski","year":"2000","journal-title":"J Intern Med"},{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0185","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s10654-018-0388-6","article-title":"Serum magnesium and risk of incident heart failure in older men: the British Regional Heart Study","volume":"33","author":"Wannamethee","year":"2018","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0190","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1007\/s10654-016-0164-4","article-title":"Serum magnesium and risk of new onset heart failure in men: the Kuopio Ischemic Heart Disease Study","volume":"31","author":"Kunutsor","year":"2016","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0195","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/01.mjt.0000209676.91582.46","article-title":"Magnesium metabolism in hypertension and type 2 diabetes mellitus","volume":"14","author":"Barbagallo","year":"2007","journal-title":"Am J Ther"},{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0200","first-page":"295","article-title":"Serum magnesium and dyslipidemia in type-2 diabetes mellitus","volume":"23","author":"Mishra","year":"2012","journal-title":"Biomed Res"},{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0205","first-page":"235","article-title":"Magnesium and selenium in diabetics with peripheral artery disease of the lower limbs","volume":"86","author":"Rusu","year":"2013","journal-title":"Clujul Med"},{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0210","doi-asserted-by":"crossref","DOI":"10.1038\/srep31214","article-title":"Dapagliflozin stimulates glucagon secretion at high glucose: experiments and mathematical simulations of human A-cells","volume":"6","author":"Pedersen","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0215","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.2844","article-title":"Effect of acute hyperinsulinemia on magnesium homeostasis in humans","volume":"33","author":"Xu","year":"2017","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0220","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.2337\/dc11-0518","article-title":"Magnesium intake and risk of type 2 diabetes: meta-analysis of prospective cohort studies","volume":"34","author":"Dong","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0225","first-page":"67","article-title":"Oral magnesium supplementation in type II diabetic patients","volume":"28","author":"Solati","year":"2014","journal-title":"Med J Islam Repub Iran"},{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0230","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3390\/nu11010044","article-title":"The effects of oral magnesium supplementation on glycemic response among type 2 diabetes patients","volume":"11","author":"ELDerawi","year":"2018","journal-title":"Nutrients."},{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0235","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/0002-9149(93)90986-M","article-title":"Effects of long-term oral magnesium chloride replacement in congestive heart failure secondary to coronary artery disease","volume":"72","author":"Bashir","year":"1993","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0240","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000485212","article-title":"Magnesium in chronic kidney disease: should we care?","volume":"45","author":"van de Wal-Visscher","year":"2018","journal-title":"Blood Purif"},{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0245","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1093\/ndt\/gfs268","article-title":"Hypomagnesemia as a risk factor for the non-recovery of the renal function in critically ill patients with acute kidney injury","volume":"28","author":"Alves","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jdiacomp.2019.06.007_bb0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41100-017-0142-7","article-title":"Cardiovascular disease, mortality, and magnesium in chronic kidney disease: growing interest in magnesium-related interventions","volume":"4","author":"Ikee","year":"2018","journal-title":"Ren Replace Ther"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872719305252?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872719305252?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T18:58:35Z","timestamp":1567796315000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872719305252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S1056872719305252"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2019.06.007","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes: A post hoc analysis of 10 randomized, placebo-controlled trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2019.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019","name":"copyright","label":"Copyright"}],"article-number":"107402"}}